DDW Editor Reece Armstrong speaks to Cassie Gorsuch, Vice President, Gene Therapy, at Precision BioSciences about limitations in treating hepatitis B (HBV) and the company’s recent clinical trial application (CTA) approval in Moldova for its lead candidate PBGENE-HBV. RA: What are the limitations of current standard-of-care treatments for HBV?  CG: There is a large unmet […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!